Upregulation of MAPK/MCL-1 Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML

被引：5

作者：

Zhang, Qi ^{[1
]}

Han, Lina ^{[1
,2
]}

Shi, Ce

Pan, Rongqing ^{[1
]}

Ma, Man Chun John ^{[3
,4
]}

Ryan, Jeremy ^{[5
]}

Kurtz, Stephen E. ^{[6
]}

Mu, Hong ^{[1
]}

Ruvolo, Vivian ^{[2
]}

Ma, Helen ^{[1
]}

Andreeff, Michael ^{[1
]}

Mi, Yingchang ^{[7
]}

Tyner, Jeffrey W. ^{[8
]}

Leverson, Joel ^{[9
]}

Letai, Anthony ^{[10
]}

Davis, Richard Eric ^{[3
,4
]}

Konopleva, Marina ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[2] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Myeloma, Houston, TX USA

[5] Dana Farber Canc Inst, Harvard Med Sch, Boston, MA USA

[6] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[7] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Hosp Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China

[8] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR USA

[9] AbbVie Inc, N Chicago, IL USA

[10] Dana Farber Canc Inst, Boston, MA USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.101.101

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

101

引用

页数：5

共 50 条

[1] Upregulation of MCL-1 through MAPK Activation Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML
Zhang, Qi
Han, Lina
Shi, Ce
Jacamo, Rodrigo
Pan, Rongqing
John, Ma Man Chun
Jeremy, Ryan
Kurtz, Stephen
Mu, Hong
Ruvolo, Vivian
Ma, Helen
Andreeff, Michael
Mi, Yingchang
Tyner, Jeferrey
Leverson, Joel
Letai, Anthony
Davis, Richard Eric
Konopleva, Marina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S285 - S285
[2] Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Qi Zhang
Bridget Riley-Gillis
Lina Han
Yannan Jia
Alessia Lodi
Haijiao Zhang
Saravanan Ganesan
Rongqing Pan
Sergej N. Konoplev
Shannon R. Sweeney
Jeremy A. Ryan
Yulia Jitkova
Kenneth Dunner
Shaun E. Grosskurth
Priyanka Vijay
Sujana Ghosh
Charles Lu
Wencai Ma
Stephen Kurtz
Vivian R. Ruvolo
Helen Ma
Connie C. Weng
Cassandra L. Ramage
Natalia Baran
Ce Shi
Tianyu Cai
Richard Eric Davis
Venkata L. Battula
Yingchang Mi
Jing Wang
Courtney D. DiNardo
Michael Andreeff
Jeffery W. Tyner
Aaron Schimmer
Anthony Letai
Rose Ann Padua
Carlos E. Bueso-Ramos
Stefano Tiziani
Joel Leverson
Relja Popovic
Marina Konopleva
Signal Transduction and Targeted Therapy, 7
[3] Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (vol 7, pg 1, 2022)
Zhang, Qi
Riley-Gillis, Bridget
Han, Lina
Jia, Yannan
Lodi, Alessia
Zhang, Haijiao
Ganesan, Saravanan
Pan, Rongqing
Konoplev, Sergej N.
Sweeney, Shannon R.
Ryan, Jeremy A.
Jitkova, Yulia
Dunner, Kenneth, Jr.
Grosskurth, Shaun E.
Vijay, Priyanka
Ghosh, Sujana
Lu, Charles
Ma, Wencai
Kurtz, Stephen
Ruvolo, Vivian R.
Ma, Helen
Weng, Connie C.
Ramage, Cassandra L.
Baran, Natalia
Shi, Ce
Cai, Tianyu
Davis, Richard Eric
Battula, Venkata L.
Mi, Yingchang
Wang, Jing
DiNardo, Courtney D.
Andreeff, Michael
Tyner, Jeffery W.
Schimmer, Aaron
Letai, Anthony
Padua, Rose Ann
Bueso-Ramos, Carlos E.
Tiziani, Stefano
Leverson, Joel
Popovic, Relja
Konopleva, Marina
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
[4] MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models
Zhang, Qi
Han, Lina
Pan, Rongqing
Shi, Ce
Jeremy, Ryan
Ma, Man Chun John
Kurtz, Steven
Mu, Hong
Ruvolo, Vivian R.
Ma, Helen
Mi, Yingchang
Tyner, Jeffrey
Anthony, Letai
Davis, Richard Eric
Andreeff, Michael
Konopleva, Marina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S2 - S2
[5] Cytokine Crosstalk Within the Bone Marrow Microenvironment as a Novel Resistance Mechanism of Bcl-2/Mcl-1 Inhibitor Resistance in AML
Zhang, Xuan
Tao, Wenjing
Mak, Po Yee
Qi, Yuan
Ma, Wencai
Wang, Jing
Ruvolo, Vivian
Andreeff, Michael
Carter, Bing Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S208 - S208
[6] Targeting AML through apoptosis activation using Bcl-2/Mcl-1 or Bcl-2/Hdm2 inhibitor combination therapies
Wang, Youzhen
Qui, Shumei
Sanghavi, Sneha
Mulford, Lain
Lysiak, Gaelle
Chanrion, Maia
Mistry, Prakash
Pfaar, Ulrike
Schoumacher, Marie
Claperon, Audrey
Kraus-Berthier, Laurence
Banquet, Sebastien
Derreal, Alix
Fabre, Claire
Maacke, Heiko
Colland, Frederic
Geneste, Olivier
Morris, Erick
Halilovic, Ensar
CANCER RESEARCH, 2019, 79 (13)
[7] The Combination of Bcl-2 Inhibitor Venetoclax and Mcl-1 Inhibitor MIK665 induces Cell Death in HCC Cells
Walz, Franziska
Michalski, Marlen
Aschenbrenner, Elisabeth
Mueller-Schilling, Martina
Guelow, Karsten
INTERNIST, 2022, 63 (SUPPL 3): : 328 - 329
[8] Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845
Fruman, David
Juarez, Dennis
Diep, Grace
Nguyen, Falisha
Gupta, Vikas A.
Boise, Lawrence H.
BLOOD, 2019, 134
[9] Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance
Liu, Fangbing
Zhao, Qiushi
Su, Yongwei
Lv, Jing
Gai, Yuqing
Liu, Shuang
Lin, Hai
Wang, Yue
Wang, Guan
EXPERIMENTAL HEMATOLOGY, 2022, 105 : 39 - 49
[10] The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
Weller, Sandra
Toenniessen, Astrid
Schaefer, Benjamin
Beigl, Tobias
Muenchow, Alina
Bopple, Kathrin
Hofmann, Ute
Gillissen, Bernhard F.
Aulitzky, Walter E.
Kopp, Hans-Georg
Essmann, Frank
CELL DEATH DISCOVERY, 2022, 8 (01)

← 1 2 3 4 5 →